Medically minimising the impact of hypoglycaemia in type 2 diabetes: a review (Q37888723)

24 August 2017

1 reference

title

Medically minimising the impact of hypoglycaemia in type 2 diabetes: a review (English)

1 reference

24 August 2017

0 references

1 reference

Radzi M Noh

1

1 reference

24 August 2017

Alex J Graveling

series ordinal

2

1 reference

24 August 2017

Brian M Frier

series ordinal

3

1 reference

24 August 2017

language of work or name

English

0 references

publication date

14 June 2011

1 reference

Expert Opinion on Pharmacotherapy

24 August 2017

1 reference

24 August 2017

12

1 reference

24 August 2017

14

1 reference

24 August 2017

2161-2175

1 reference

Global prevalence of diabetes: estimates for the year 2000 and projections for 2030

24 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.589835

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.589835

Intensive glucose control and macrovascular outcomes in type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.589835

Effects of intensive glucose lowering in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.589835

Defining and reporting hypoglycemia in diabetes: a report from the American Diabetes Association Workgroup on Hypoglycemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.589835

Defining hypoglycaemia: what level has clinical relevance?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.589835

Preventing hypoglycaemia: what is the appropriate glucose alert value?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.589835

Changing the glucose cut-off values that define hypoglycaemia has a major effect on reported frequencies of hypoglycaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.589835

Frequency of severe hypoglycemia requiring emergency treatment in type 1 and type 2 diabetes: a population-based study of health service resource use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.589835

Hypoglycemia is more common among type 2 diabetes patients with limited health literacy: the Diabetes Study of Northern California (DISTANCE).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.589835

Partitioning the symptoms of hypoglycaemia using multi-sample confirmatory factor analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.589835

Mechanisms of hypoglycemia-associated autonomic failure and its component syndromes in diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.589835

Effect of glycemic control on glucose counterregulation during hypoglycemia in NIDDM.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.589835

Hypoglycemia-associated autonomic failure in advanced type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.589835

Increasing the decrement in insulin secretion improves glucagon responses to hypoglycemia in advanced type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.589835

Impaired awareness of hypoglycaemia: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.589835

Prevalence of impaired awareness of hypoglycaemia and frequency of hypoglycaemia in insulin-treated type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.589835

The continuous glucose monitoring system is useful for detecting unrecognized hypoglycemias in patients with type 1 and type 2 diabetes but is not better than frequent capillary glucose measurements for improving metabolic control

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.589835

Comparison of continuous blood glucose measurement with conventional documentation of hypoglycemia in patients with Type 2 diabetes on multiple daily insulin injection therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.589835

Unrecognized Hypo- and Hyperglycemia in Well-Controlled Patients with Type 2 Diabetes Mellitus: The Results of Continuous Glucose Monitoring

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.589835

Physical activity/exercise and type 2 diabetes: a consensus statement from the American Diabetes Association

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.589835

Low-dose ethanol predisposes elderly fasted patients with type 2 diabetes to sulfonylurea-induced low blood glucose.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.589835

Symptoms of hypoglycaemia in people with diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.589835

The British Diabetic Association Cohort Study, II: cause-specific mortality in patients with insulin-treated diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.589835

The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.589835

Association of hypoglycemia and cardiac ischemia: a study based on continuous monitoring

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.589835

The case for hypoglycaemia as a proarrhythmic event: basic and clinical evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.589835

Antecedent hypoglycemia impairs autonomic cardiovascular function: implications for rigorous glycemic control

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.589835

Fear of hypoglycaemia: defining a minimum clinically important difference in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.589835

The economic and quality of life impact of hypoglycemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.589835

Hypoglycaemic symptoms, treatment satisfaction, adherence and their associations with glycaemic goal in patients with type 2 diabetes mellitus: findings from the Real-Life Effectiveness and Care Patterns of Diabetes Management (RECAP-DM) Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.589835

Trends and disparities in U.S. emergency department visits for hypoglycemia, 1993-2005.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.589835

Costs of managing severe hypoglycaemia in three European countries

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.589835

Self management and patient understanding of diabetes in the older person

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.589835

A(1c) control in a primary care setting: self-titrating an insulin analog pre-mix (INITIATEplus trial).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.589835

Hypoglycemia anticipation, awareness and treatment training (HAATT) reduces occurrence of severe hypoglycemia among adults with type 1 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.589835

Randomized controlled clinical trial of Blood Glucose Awareness Training (BGAT III) in Switzerland and Germany

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.589835

Self-monitoring of blood glucose in type 2 diabetes: systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.589835

Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.589835

Spurious reporting of nocturnal hypoglycemia by CGMS in patients with tightly controlled type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.589835

A randomised controlled trial to compare minimally invasive glucose monitoring devices with conventional monitoring in the management of insulin-treated diabetes mellitus (MITRE).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.589835

Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.589835

Systematic Review: Comparative Effectiveness and Safety of Oral Medications for Type 2 Diabetes Mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.589835

Impact of therapeutic advances on hypoglycaemia in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.589835

Addition of thiazolidinedione or exenatide to oral agents in type 2 diabetes: a meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.589835

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.589835

Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.589835

A Systematic Review and Meta-Analysis of Hypoglycemia and Cardiovascular Events: A comparison of glyburide with other secretagogues and with insulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.589835

Lower incidence of severe hypoglycaemia in patients with type 2 diabetes treated with glimepiride versus glibenclamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.589835

GUIDE study: double-blind comparison of once-daily gliclazide MR and glimepiride in type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.589835

Meglitinide analogues in the treatment of type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.589835

Improved control of mealtime glucose excursions with coadministration of nateglinide and metformin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.589835

Effect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.589835

Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.589835

Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. HOE 901/3002 Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.589835

Safety and efficacy of insulin glargine (HOE 901) versus NPH insulin in combination with oral treatment in Type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.589835

The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.589835

Insulin analogues (insulin detemir and insulin aspart) versus traditional human insulins (NPH insulin and regular human insulin) in basal-bolus therapy for patients with type 1 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.589835

Optimal insulin regimens in type 2 diabetes mellitus: systematic review and meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.589835

Once-daily basal insulin glargine versus thrice-daily prandial insulin lispro in people with type 2 diabetes on oral hypoglycaemic agents (APOLLO): an open randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.589835

Three-year efficacy of complex insulin regimens in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.589835

Effects of metformin and thiazolidinediones on suppression of hepatic glucose production and stimulation of glucose uptake in type 2 diabetes: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.589835

Glucagon-like peptide-1 and the islet beta-cell: augmentation of cell proliferation and inhibition of apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.589835

Addition of pioglitazone or bedtime insulin to maximal doses of sulfonylurea and metformin in type 2 diabetes patients with poor glucose control: a prospective, randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.589835

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.589835

Glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.589835

Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.589835

Exenatide compared with long-acting insulin to achieve glycaemic control with minimal weight gain in patients with type 2 diabetes: results of the Helping Evaluate Exenatide in patients with diabetes compared with Long-Acting insulin (HEELA) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.589835

Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.589835

10-year follow-up of intensive glucose control in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.589835

Evidence that vildagliptin attenuates deterioration of glycaemic control during 2-year treatment of patients with type 2 diabetes and mild hyperglycaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.589835

The scientific evidence: vildagliptin and the benefits of islet enhancement

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.589835

Severe hypoglycemia monitoring and risk management procedures in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.589835

ACCORD glycemia results continue to puzzle

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.589835

Effects of intensive therapy and antecedent hypoglycemia on counterregulatory responses to hypoglycemia in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.589835

Effects of controlled hypoglycaemia on cardiac repolarisation in patients with type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.589835

Vascular disease and diabetes: is hypoglycaemia an aggravating factor?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.589835

Frequency and predictors of hypoglycaemia in Type 1 and insulin-treated Type 2 diabetes: a population-based study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.589835

Risk of hypoglycaemia in types 1 and 2 diabetes: effects of treatment modalities and their duration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.589835

Altered Hierarchy of Protective Responses Against Severe Hypoglycemia in Normal Aging in Healthy Men

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.589835

Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial: Design and Methods

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.589835

Group based training for self-management strategies in people with type 2 diabetes mellitus

21 January 2018

1 reference

30 December 2023

https://opencitations.net/index/api/v1/citations/10.1002/14651858.CD003417.PUB2

Identifiers

DOI

10.1517/14656566.2011.589835

1 reference

24 August 2017

1 reference